ClinicalTrials.gg
CompletedNCT06847464Updated Jul 1, 2025

A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.

A Phase 1 interventional study of EDP-323 and Itraconazole in RSV Infection and Drug Drug Interaction (DDI), sponsored by Enanta Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Enanta Pharmaceuticals, Inc · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc — 1 open to participants now, 1 under way, none of them phase 3. Respiratory Syncytial Virus Infections · Enanta Pharmaceuticals, Inc.

Enrollment
10th of 14
48 · median 77
Started
2025
with 1 other
Phase 1
9 of 14
none open now
Registered
12th of 14
by date

Among the 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc, this one is the 10th largest by enrollment, is one of 2 that started in 2025, is one of 9 in phase 1, and was the 12th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Respiratory Syncytial Virus Infections by Enanta Pharmaceuticals, Inc, or all of them as a file.
02

Study summary

The primary aim of the study is to assess the effect of itraconazole, carbamazepine, quinidine, and fluconazole individually on the pharmacokinetics and safety of EDP-323 in healthy adult participants. Each participant's duration in the study will be dependent upon which study part they are enrolled.

03

Conditions studied

  • RSV Infection
  • Drug Drug Interaction (DDI)

Keywords

  • Drug Drug Interaction
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An document signed and dated by the subject.
  • Healthy male and female subjects of any ethnic origin between the ages of 18 and 65 years, inclusive.
  • Screening (BMI) of 18 to 30 kg/m2 with a minimum body weight of50 kg
  • Female subjects of must agree to use two effective methods of from the date of Screening until 30 days after the last dose of EDP-323. A male participant who has not had a vasectomy and is sexually active with a woman of childbearing potential must agree to use effective contraception from the date of Screening to 90 days after his last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • evidence or history of illness or disease
  • Pregnant or nursing females
  • History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection
  • A positive urine drug screen at Screening or Day -1
  • Current tobacco smokers or use of tobacco within 3 months prior to Screening.
  • Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy)
  • History of regular alcohol consumption exceeding protocol limits
  • Participation in a clinical trial within 28 days prior to the first dose of study drug
  • For Part 2 and Part 3 participants, the following cardiovascular abnormalities:
  • QRS duration >110 ms
  • Incomplete right bundle branch block or any complete bundle branch block
  • Heart rate \<40 or >90 beats per minute (per vital sign capture while rested)
  • History of unexplained syncope, structural heart disease, or clinically significant arrhythmias
  • Personal or family history of long syndrome (genetically proven or suggested by sudden death of a close relative due to cardiac causes at a young age) or Brugada syndrome
  • PR interval >220 ms or any 2nd or 3rd degree AV block
  • Ventricular pre-excitation
  • Other exclusions for Part 2 (carbamazepine) participants
  • Participants of Asian ancestry with HLA allele B*1502 in this population
  • , white blood cell count or below the lower limit of normal, due to reported incidence of agranulocytosis and aplastic anemia with carbamazepine
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    EDP-323 and itraconazole interaction (Part 1)

    Subjects will receive EDP-323 and itraconazole on respective dosing days

    Drug: EDP-323 · Drug: Itraconazole

  • Experimental
    EDP-323 and carbamazepine interaction (Part 2)

    Subjects will receive EDP-323 and carbamazepine on respective dosing days

    Drug: EDP-323 · Drug: carbamazepine

  • Experimental
    EDP-323 and quinidine interaction (Part 3)

    Subjects will receive EDP-323 and quinidine on respective dosing days

    Drug: EDP-323 · Drug: Quinidine

  • Experimental
    EDP-323 and fluconazole interaction (Part 4)

    Subjects will receive EDP-323 and fluconazole on respective dosing days

    Drug: EDP-323 · Drug: fluconazole

Interventions

  • Subjects will receive EDP-323 on Days 1 and 14

  • Subjects will receive itraconazole QD Days 5-18

  • Subjects will receive EDP-323 on Days 1 and 23

  • Subjects will receive carbamazepine on Days 5 - 27

  • Subjects will receive EDP-323 on Days 1 and 8

  • Subjects will receive quinidine on Days 5-12

  • Subjects will receive EDP-323 on Days 1 and 14

  • Subjects will receive fluconazole on Days 5-18

06

What researchers measure

Primary outcomes

  1. Cmax of EDP-323 with and without coadministration with Itraconazole

    Time frame: Day 1 through Day 19

  2. AUC of EDP-323 with and without coadministration with Itraconazole

    Time frame: Day 1 through Day 19

  3. Cmax of EDP-323 with and without coadministration with Carbamazepine

    Time frame: Day 1 through Day 28

  4. AUC of EDP-323 with and without coadministration with Carbamazepine

    Time frame: Day 1 through Day 28

  5. Cmax of EDP-323 with and without coadministration with Quinidine

    Time frame: Day 1 through Day 13

  6. AUC of EDP-323 with and without coadministration with Quinidine

    Time frame: Day 1 through Day 13

  7. Cmax of EDP-323 with and without coadministration with fluconazole

    Time frame: Day 1 through Day 19

  8. AUC of EDP-323 with and without coadministration with fluconazole

    Time frame: Day 1 through Day 19

Secondary outcomes

  1. Safety measured by adverse events

    Time frame: Up to 34 Days

07

Study locations

1 site
  • ICON, plc
    San Antonio, Texas 78209, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in May 2025, 3 months.

Of 44 industry-sponsored phase 1 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 3 months is below that.

Counting every sponsor, half of 57 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Feb 26, 2025
StartActual
Jan 27, 2025
Primary completionActual
May 24, 2025
CompletionActual
Jun 1, 2025
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06847464
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
Jan 27, 2025
Primary completion
May 24, 2025
Completion
Jun 1, 2025
Last update
Jul 1, 2025

Study contacts

Enanta Pharmaceuticals, Inc
study director · Enanta Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EDP-323

Start the discussion